Aptose Biosciences Inc (NASDAQ: APTO)’s stock price has dropped by -45.71 in relation to previous closing price of 3.15. Nevertheless, the company has seen a loss of -50.86% in its stock price over the last five trading days. globenewswire.com reported 2025-03-28 that Tuspetinib Triple Drug Frontline Therapy Advancing in TUSCANY Clinical Trial Results to Date Highlight TUS Potential as an Ideal Third Drug to Include in AML Triplet Therapy Aptose Signs Debt Conversion Agreement with Hanmi SAN DIEGO and TORONTO, March 28, 2025 (GLOBE NEWSWIRE) — Aptose Biosciences Inc. (“Aptose” or the “Company”) (NASDAQ: APTO, TSX: APS), a clinical-stage precision oncology company developing a tuspetinib (TUS)-based triple drug frontline therapy to treat patients with newly diagnosed acute myeloid leukemia (AML), today announced financial results for the year ended December 31, 2024, and provided a corporate update. “During 2024 and into 2025, we continue to advance our lead investigational drug tuspetinib in combination with venetoclax (VEN) and azacitidine (AZA) for frontline treatment of newly diagnosed acute myeloid leukemia (AML),” said William G.
Is It Worth Investing in Aptose Biosciences Inc (NASDAQ: APTO) Right Now?
The stock has a 36-month beta value of 1.03. Opinions on the stock are mixed, with 1 analysts rating it as a “buy,” 1 as “overweight,” 0 as “hold,” and 0 as “sell.”
The public float for APTO is 1.61M, and at present, short sellers hold a 3.30% of that float. On April 02, 2025, the average trading volume of APTO was 220.96K shares.
APTO’s Market Performance
APTO stock saw a decrease of -50.86% in the past week, with a monthly decline of -40.00% and a quarterly a decrease of -76.35%. The volatility ratio for the week is 15.83%, and the volatility levels for the last 30 days are 12.51% for Aptose Biosciences Inc (APTO). The simple moving average for the past 20 days is -49.85% for APTO’s stock, with a -83.84% simple moving average for the past 200 days.
Analysts’ Opinion of APTO
Many brokerage firms have already submitted their reports for APTO stocks, with Cantor Fitzgerald repeating the rating for APTO by listing it as a “Overweight.” The predicted price for APTO in the upcoming period, according to Cantor Fitzgerald is $10 based on the research report published on October 19, 2020 of the previous year 2020.
Alliance Global Partners, on the other hand, stated in their research note that they expect to see APTO reach a price target of $12. The rating they have provided for APTO stocks is “Buy” according to the report published on September 22nd, 2020.
Maxim Group gave a rating of “Buy” to APTO, setting the target price at $16 in the report published on February 20th of the previous year.
APTO Trading at -61.40% from the 50-Day Moving Average
After a stumble in the market that brought APTO to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -96.69% of loss for the given period.
Volatility was left at 12.51%, however, over the last 30 days, the volatility rate increased by 15.83%, as shares sank -33.98% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -73.35% lower at present.
During the last 5 trading sessions, APTO fell by -50.86%, which changed the moving average for the period of 200-days by -93.74% in comparison to the 20-day moving average, which settled at $3.41. In addition, Aptose Biosciences Inc saw -74.70% in overturn over a single year, with a tendency to cut further losses.
Insider Trading
Reports are indicating that there were more than several insider trading activities at APTO starting from Rice William G., who purchase 100,000 shares at the price of $0.20 back on Nov 25 ’24. After this action, Rice William G. now owns 613,252 shares of Aptose Biosciences Inc, valued at $20,000 using the latest closing price.
Stock Fundamentals for APTO
Current profitability levels for the company are sitting at:
- -51.23 for the present operating margin
- 0.52 for the gross margin
The net margin for Aptose Biosciences Inc stands at -50.67. The total capital return value is set at -31.16. Equity return is now at value -694.13, with -220.02 for asset returns.
Based on Aptose Biosciences Inc (APTO), the company’s capital structure generated 6.76 points at debt to capital in total, while cash flow to debt ratio is standing at -3.49. The debt to equity ratio resting at -1.17. The interest coverage ratio of the stock is -66.22.
When we switch over and look at the enterprise to sales, we see a ratio of 21.18. The liquidity ratio also appears to be rather interesting for investors as it stands at 2.14.
Conclusion
To sum up, Aptose Biosciences Inc (APTO) has seen a bad performance recently. Analysts have differing views on the stock, with some seeing it as a “buy” and others as a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
